nach oben

Tipp

State-of-the-Art-Bildgebung von neuroendokrinen Tumoren

Zeitschrift:: Journal für Klinische Endokrinologie und Stoffwechsel

Autoren:: PD Dr. Daniel Putzer, Michael Gabriel, Reto Josef Bale, Werner Rudolf Jaschke

» Zum Volltext PDF-Version jetzt herunterladen

Wichtige Hinweise

Hinweis des Verlags

Der Verlag bleibt in Hinblick auf geografische Zuordnungen und Gebietsbezeichnungen in veröffentlichten Karten und Institutsadressen neutral.

Zusammenfassung

Die PET/CT hat als Hybridbildgebung die Vorteile einer exakten Darstellung anatomisch-morphologischer Verhältnisse in der CT und einer effektiven Lokalisierung von Tumorherden in der PET unter Verwendung von Somatostatin(SST)-Analoga vereint. Die Weiterentwicklung radioaktiv markierter Derivate synthetisch hergestellter SST-Analoga und die technische Verbesserung der PET-Technik, mit höherer Auflösung bei gleichzeitig spezifischer Bindung der Radiopharmaka an verschiedene Somatostatin-Rezeptor-Subtypen hat zur Entwicklung von neuen Anwendungen in der Diagnose von neuroendokrinen Tumoren (NET) beigetragen.

Tsoucalas G, Karamanou M, Androutsos G (2011) The eminent German pathologist Siegfried Oberndorfer (1876–1944) and his landmark work on carcinoid tumors. Ann Gastroenterol 24(2):98–100 PubMedPubMedCentral

de Herder WW (2014) Heroes in endocrinology: Nobel prizes. Endocr Connect 3(3):R94–R104 PubMedPubMedCentralCrossRef

Modlin IM, Champaneria MC, Bornschein J, Kidd M (2006) Evolution of the diffuse neuroendocrine system—clear cells and cloudy origins. Neuroendocrinology 84(2):69–82 PubMedCrossRef

Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A, Meric-Bernstam F (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26(26):4311–4318 PubMedPubMedCentralCrossRef

Tang LH, Untch BR, Reidy DL, O’Reilly E, Dhall D, Jih L, Basturk O, Allen PJ, Klimstra DS (2016) Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas. Clin Cancer Res 22(4):1011–1017 PubMedCrossRef

Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Díaz-Pérez JA, Martínez Del Prado MP, Alonso Orduña V, Sevilla-García I, Villabona-Artero C, Beguiristain-Gómez A, Llanos-Muñoz M, Marazuela M, Alvarez-Escola C, Castellano D, Vilar E, Jiménez-Fonseca P, Teulé A, Sastre-Valera J, Benavent-Viñuelas M, Monleon A, Salazar R (2010) Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 21(9):1794–1803 PubMedCrossRef

Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM (2011) The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 40(1):1–18 PubMedCrossRef

Modlin IM, Lye KD, Kidd M (2003) A 5‑decade analysis of 13,715 carcinoid tumors. Cancer 97:934–959 PubMedCrossRef

Fraenkel M, Kim M, Faggiano A, de Herder WW, Valk GD (2014) Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr Relat Cancer 21(3):R153–R163 PubMedCrossRef

10.

Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, Kos-Kudla B, Kwekkeboom D, Rindi G, Klöppel G, Reed N, Kianmanesh R, Jensen RT et al (2016) Consensus guidelines update for the management of functional p‑NETs (F-p-NETs) and non-functional p‑NETs (NF-p-NETs). Neuroendocrinology 103(2):153–171 PubMedPubMedCentralCrossRef

11.

Baxi AJ, Chintapalli K, Katkar A, Restrepo CS, Betancourt SL, Sunnapwar A (2017) Multimodality imaging findings in carcinoid tumors: a head-to-toe spectrum. Radiographics 37(2):516–536 PubMedCrossRefPubMedCentral

12.

Di Martino M, García Sanz Í, Muñoz de Nova JL, Marín Campos C, Martín-Pérez E (2015) Comb sign in intestinal obstruction secondary to desmoplastic reaction due to an ileal neuroendocrine tumor. Rev Esp Enferm Dig 107(11):697–698 PubMedPubMedCentral

13.

Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, Scoazec J‑Y, Salazar R, Sauvanet A, Kianmanesh R et al (2012) ENETS consensus. Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 95(2):98–119 PubMedPubMedCentralCrossRef

14.

Hannah-Shmouni F, Stratakis CA, Koch CA (2016) Flushing in (neuro)endocrinology. Rev Endocr Metab Disord 17(3):373–380 PubMedPubMedCentralCrossRef

15.

Reubi JC, Schaer JC, Markwalder R, Waser B, Horisberger U, Laissue JA (1997) Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potential relevance. Yale J Biol Med 70:471–479 PubMedPubMedCentral

16.

Hoyer D, Epelbaum J, Feniuk W et al (2000) Soma-tostatin receptors. In: Girdlestrom D (Hrsg) The IUPHAR compendium of receptor characterization and classification. IUPHAR, London, S 354–364

17.

Reubi JC (1997) Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy. Q J Nucl Med 41:63–70 PubMedPubMedCentral

18.

Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, Ausema L, Lameris JS, Reubi JC, Lamberts SW (1989) Localization of endocrine related tumors with radioiodinated analogue of somatostatin. Lancet 333(8632):242–244. https://doi.org/10.1016/S0140-6736(89)91258-0 CrossRef

19.

Balon HR, Goldsmith SJ, Siegel BA, Silberstein EB, Krenning EP, Lang O, Donohoe KJ (2001) Procedure guideline for somatostatin receptor scintigraphy with ¹¹¹In-pentetreotide. J Nucl Med 42:1134–1138 PubMedPubMedCentral

20.

Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, Von Guggenberg E, Bale R, Virgolini IJ (2007) 68 Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48(4):508–518 PubMedCrossRefPubMedCentral

21.

Sundin A, Arnold R, Baudin E, Cwikla JB, Eriksson B, Fanti S, Fazio N, Giammarile F, Hicks RJ, Kjaer A, Krenning E, Kwekkeboom D, Lombard-Bohas C, O’Connor JM, O’Toole D, Rockall A, Wiedenmann B, Valle JW, Vullierme MP et al (2017) ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine & hybrid imaging. Neuroendocrinology. https://doi.org/10.1159/000471879 CrossRefPubMedPubMedCentral

22.

Olsen IH, Langer SW, Federspiel BH, Oxbøl J, Loft A, Berthelsen AK, Mortensen J, Oturai P, Knigge U, Kjær A (2016) (68)Ga-DOTATOC PET and gene expression profile in patients with neuroendocrine carcinomas: strong correlation between PET tracer uptake and gene expression of somatostatin receptor subtype 2. Am J Nucl Med Mol Imaging 6(1):59–72 PubMedPubMedCentral

23.

Yu F, Venzon DJ, Serrano J, Goebel SU, Doppman JL, Gibril F, Jensen RT (1999) Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol 17:615–630 PubMedCrossRefPubMedCentral

24.

Panzuto F, Nasoni S, Falconi M (2005) Prognostic factors and survival in endocrine tumor patient: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 12:1083–1092 PubMedCrossRefPubMedCentral

25.

Koopmans KP, de Vries EG, Kema IP, Elsinga PH, Neels OC, Sluiter WJ, van der Horst-Schrivers AN, Jager PL (2006) Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol 7(9):728–734 PubMedCrossRefPubMedCentral

26.

Ruf J, Schiefer J, Furth C, Kosiek O, Kropf S, Heuck F, Denecke T, Pavel M, Pascher A, Wiedenmann B, Amthauer H (2011) 68 Ga-DOTATOC PET/CT of neuroendocrine tumors: spotlight on the CT phases of a triple-phase protocol. J Nucl Med 52(5):697–704 PubMedCrossRefPubMedCentral

27.

Ambrosini V, Nanni C, Zompatori M, Campana D, Tomassetti P, Castellucci P, Allegri V, Rubello D, Montini G, Franchi R, Fanti S (2010) (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 37(4):722–727 PubMedCrossRefPubMedCentral

28.

Karaosmanoglu AD, Onur MR, Ozmen MN, Akata D, Karcaaltincaba M (2016) Magnetic resonance imaging of liver metastasis. Semin Ultrasound CT MR 37(6):533–548 PubMedCrossRefPubMedCentral

29.

Zhang H, Zeng D, Zhang H, Wang J, Liang Z, Ma J (2017) Applications of nonlocal means algorithm in low-dose X‑ray CT image processing and reconstruction: a review. Med Phys 44(3):1168–1185 PubMedPubMedCentralCrossRef

30.

Jensen K, Andersen HK, Tingberg A, Reisse C, Fosse E, Martinsen AC (2016) Improved liver lesion conspicuity with iterative reconstruction in computed tomography imaging. Curr Probl Diagn Radiol 45(5):291–296 PubMedCrossRef

31.

Catalano C, Francone M, Ascarelli A, Mangia M, Iacucci I, Passariello R (2007) Optimizing radiation dose and image quality. Eur Radiol 17(Suppl 6):F26–F32 PubMedCrossRef

32.

Canadian Agency for Drugs and Technologies in Health (2014) Radiation emissions from computed tomography: a review of the risk of cancer and guidelines. Rapid response reports. CADTH, Ottawa

33.

Pinker K, Riedl C, Weber WA (2017) Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-017-3687-3 CrossRefPubMedPubMedCentral

34.

Pape UF, Maasberg S, Jann H, Pschowski R, Krüger S, Prasad V, Denecke T, Wiedenmann B, Pascher A (2016) Management of follow-up of neuroendocrine neoplasias. Best Pract Res Clin Endocrinol Metab 30(1):129–140 PubMedCrossRef

35.

Jones T, Townsend D (2017) History and future technical innovation in positron emission tomography. J Med Imaging (Bellingham) 4(1):11013 CrossRef

36.

Panagiotidis E, Alshammari A, Michopoulou S, Skoura E, Naik K, Maragkoudakis E, Mohmaduvesh M, Al-Harbi M, Belda M, Caplin ME, Toumpanakis C, Bomanji J (2017) Comparison of the impact of 68Ga-DOTATATE and 18F-FDG PET/CT on clinical management in patients with neuroendocrine tumors. J Nucl Med 58(1):91–96 PubMedCrossRefPubMedCentral

37.

Pasquali C, Rubello D, Sperti C, Gasparoni P, Liessi G, Chierichetti F, Ferlin G, Pedrazzoli S (1998) Neuroendocrine tumor imaging: can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? World J Surg 22(6):588–592 PubMedCrossRefPubMedCentral

38.

Has Simsek D, Kuyumcu S, Turkmen C, Sanlı Y, Aykan F, Unal S, Adalet I (2014) Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors? J Nucl Med 55(11):1811–1817 PubMedCrossRefPubMedCentral

39.

Cuccurullo V, Prisco MR, Di Stasio GD, Mansi L (2017) Nuclear medicine in patients with NET: radiolabeled somatostatin analogues and their brothers. Curr Radiopharm. https://doi.org/10.2174/1874471010666170323115136 CrossRefPubMedPubMedCentral

40.

Minn H, Kemppainen J, Kauhanen S, Forsback S, Seppänen M (2014) 18F-fluorodihydroxyphenylalanine in the diagnosis of neuroendocrine tumors. PET Clin 9(1):27–36 PubMedCrossRef

41.

Koopmans KP, Neels OC, Kema IP, Elsinga PH, Sluiter WJ, Vanghillewe K, Brouwers AH, Jager PL, de Vries EG (2008) Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol 26(9):1489–1495 PubMedCrossRef

42.

Montravers F, Grahek D, Kerrou K, Ruszniewski P, de Beco V, Aide N, Gutman F, Grangé JD, Lotz JP, Talbot JN (2006) Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? J Nucl Med 47(9):1455–1462 PubMed

43.

Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, van Hagen M, Postema PT, de Jong M, Reubi JC et al (1993) Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20:716–731 PubMedCrossRef

44.

Papotti M, Bongiovanni M, Volante M, Allìa E, Landolfi S, Helboe L, Schindler M, Cole SL, Bussolati G (2002) Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 440:461–475 PubMedCrossRef

45.

Reubi JC, Kvols LK, Waser B, Nagorney DM, Heitz PU, Charboneau JW, Reading CC, Moertel C (1990) Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 50:5969–5977 PubMed

46.

Deroose CM, Hindié E, Kebebew E, Goichot B, Pacak K, Taïeb D, Imperiale A (2016) Molecular imaging of gastroenteropancreatic neuroendocrine tumors: current status and future directions. J Nucl Med 57(12):1949–1956 PubMedPubMedCentralCrossRef

47.

Decristoforo C (2012) Gallium-68—a new opportunity for PET available from a long shelf-life generator—automation and applications. Curr Radiopharm 5(3):212–220 PubMedCrossRef

48.

Kilian K (2014) 68 Ga-DOTA and analogs: current status and future perspectives. Rep Pract Oncol Radiother 19(Suppl):S13–S21. https://doi.org/10.1016/j.rpor.2014.04.016 CrossRefPubMedPubMedCentral

49.

Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J (2010) The role of 68 Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med 51(6):875–882 PubMedCrossRef

50.

Sainz-Esteban A, Olmos R, González-Sagrado M, González ML, Ruiz MÁ, García-Talavera P, Gamazo C, Villanueva JG, Cobo A, de Luis D (2015) Contribution of 111In-pentetreotide SPECT/CT imaging to conventional somatostatin receptor scintigraphy in the detection of neuroendocrine tumours. Nucl Med Commun 36(3):251–259 PubMedCrossRefPubMedCentral

51.

Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, de Jong M, de Herder WW, Krenning EP (2010) Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 17(1):R53–R73 PubMedCrossRefPubMedCentral

52.

Gabriel M, Oberauer A, Dobrozemsky G, Decristoforo C, Putzer D, Kendler D, Uprimny C, Kovacs P, Bale R, Virgolini IJ (2009) 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med 50(9):1427–1434 PubMedCrossRefPubMedCentral

53.

Frilling A, Sotiropoulos GC, Radtke A, Malago M, Bockisch A, Kuehl H, Li J, Broelsch CE (2010) The impact of 68 Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg 252(5):850–856 PubMedCrossRefPubMedCentral

54.

Virgolini I, Gabriel M, Kroiss A, von Guggenberg E, Prommegger R, Warwitz B, Nilica B, Roig LG, Rodrigues M, Uprimny C (2016) Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrinetumours. Eur J Nucl Med Mol Imaging 43(11):2072–2083 PubMedPubMedCentralCrossRef

55.

Partelli S, Bartsch DK, Capdevila J, Chen J, Knigge U, Niederle B, Nieveen van Dijkum EJ, Pape UF, Pascher A, Ramage J, Reed N, Ruszniewski P, Scoazec JY, Toumpanakis C, Kianmanesh R, Falconi M et al (2017) ENETS consensus guidelines for standard of care in neuroendocrine tumours: surgery for small intestinal and pancreatic neuroendocrine tumours. Neuroendocrinology. https://doi.org/10.1159/000464292 CrossRefPubMedPubMedCentral

56.

Kaltsas G, Caplin M, Davies P, Ferone D, Garcia-Carbonero R, Grozinsky-Glasberg S, Hörsch D, Tiensuu Janson E, Kianmanesh R, Kos-Kudla B, Pavel M, Rinke A, Falconi M, de Herder WW et al (2017) ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pre- and perioperative therapy in patients with neuroendocrine tumors. Neuroendocrinology. https://doi.org/10.1159/000461583 CrossRefPubMedPubMedCentral

57.

Pavel M, Valle JW, Eriksson B, Rinke A, Caplin M, Chen J, Costa F, Falkerby J, Fazio N, Gorbounova V, de Herder W, Kulke M, Lombard-Bohas C, O’Connor J, Sorbye H, Garcia-Carbonero R et al (2017) ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: systemic therapy—biotherapy and novel targeted agents. Neuroendocrinology. https://doi.org/10.1159/000471880 CrossRefPubMedPubMedCentral

58.

Garcia-Carbonero R, Rinke A, Valle JW, Fazio N, Caplin M, Gorbounova V, O’Connor J, Eriksson B, Sorbye H, Kulke M, Chen J, Falkerby J, Costa F, de Herder W, Lombard-Bohas C, Pavel M et al (2017) ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms. Systemic therapy 2: chemotherapy. Neuroendocrinology. https://doi.org/10.1159/000473892 CrossRefPubMedPubMedCentral

59.

Pavel ME, Baudin E, Öberg KE, Hainsworth JD, Voi M, Rouyrre N, Peeters M, Gross DJ, Yao JC (2017) Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT‑2 study. Ann Oncol. https://doi.org/10.1093/annonc/mdx193 CrossRefPubMedPubMedCentral

60.

Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R, Borbath I, Cwikla J, Toumpanakis C, Kaltsas G, Davies P, Hörsch D, Tiensuu Janson E, Ramage J et al (2017) ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues. Neuroendocrinology. https://doi.org/10.1159/000475526 CrossRefPubMedPubMedCentral

61.

Yang J, Kan Y, Ge BH, Yuan L, Li C, Zhao W (2014) Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis. Acta Radiol 55(4):389–398 PubMedCrossRefPubMedCentral

62.

Johnbeck CB, Knigge U, Kjær A (2014) PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. Future Oncol 10(14):2259–2277 PubMedCrossRefPubMedCentral

63.

Schillaci O, Spanu A, Scopinaro F, Falchi A, Danieli R, Marongiu P, Pisu N, Madeddu G, Delle Fave G, Madeddu G (2003) Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors. J Nucl Med 44:359–368 PubMedPubMedCentral

64.

Jamar F, Fiasse R, Leners N, Pauwels S (1995) Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management. J Nucl Med 36:542–554 PubMedPubMedCentral

65.

Gotthardt M, Dirkmorfeld LM, Wied MU, Rinke A, Béhé MP, Schlieck A, Höffken H, Alfke H, Joseph K, Klose KJ, Behr TM, Arnold R (2003) Influence of somatostatin receptor scintigraphy and CT/MRI on the clinical management of patients with gastrointestinal neuroendocrine tumors: an analysis in 188 patients. Digestion 68:80–85 PubMedCrossRefPubMedCentral

66.

Alberini JL, Edeline V, Giraudet AL, Champion L, Paulmier B, Madar O, Poinsignon A, Bellet D, Pecking AP (2011) Single photon emission tomography/computed tomography (SPET/CT) and positron emission tomography/computed tomography (PET/CT) to image cancer. J Surg Oncol 103(6):602–606 PubMedCrossRefPubMedCentral

67.

Geijer H, Breimer LH (2013) Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 40(11):1770–1780 PubMedCrossRefPubMedCentral

Titel: State-of-the-Art-Bildgebung von neuroendokrinen Tumoren
Autoren:: PD Dr. Daniel Putzer
Michael Gabriel
Reto Josef Bale
Werner Rudolf Jaschke
Publikationsdatum: 03.02.2020
Schlagwörter: Radiologie
Innere Medizin
DOI: https://doi.org/10.1007/s41969-019-00088-3
Verlag: Springer Vienna
Zeitschrift: Journal für Klinische Endokrinologie und Stoffwechsel Austrian Journal of Clinical Endocrinology and Metabolism
Print ISSN: 1998-7773
Elektronische ISSN: 1998-7781

Bildnachweise

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

State-of-the-Art-Bildgebung von neuroendokrinen Tumoren

Hinweis des Verlags

Zusammenfassung

Neue App: SpringerMed Fortbildung

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Hinweis des Verlags

Zusammenfassung

Neue App: SpringerMed Fortbildung